Japan’s M&A market stands at a historic crossroads, having recorded total deal value of US$165.4 billion, its highest in a decade to following a massive 52.5% year-on-year jump, according to Mergermarket data. On one hand, corporate governance reforms and favorable financing are driving an unprecedented wave of carve-outs and take-privates to feed a deal-hungry market. On the other hand, shifting geopolitical tides are pushing Japan toward a more protectionist stance, defined by a drive for supply chain independence and tighter scrutiny of foreign capital. Our panel of experts will share their views on the outlook for the market and what the industry must do to maintain the momentum.  

• How are Japan's ongoing corporate governance reforms and current currency dynamics reshaping deal flow and valuations for global acquirers? 
• How can investors identify the next prime targets for carve-outs and take-privates? 
• How does Japan's insulation from global volatility drive M&A momentum?  
• Will geopolitical risks and tighter foreign capital scrutiny derail this trend in the next 12-36 months?

A saturated domestic market, geopolitical shifts, and supply chain relocations continue to push Japanese firms toward outbound acquisitions, though activity is currently dominated by tech mega-deals. Once known for paying high premiums, traditional Japanese corporates have grown remarkably conservative and are noticeably absent from multi-billion-dollar global bids. However, Tokyo Stock Exchange capital efficiency mandates and the drive to deploy 'trapped capital' as a hedge against the weak yen ensure a solid outbound pipeline for 2026.  panel of experts will share their views on the outlook for the market and what the industry must do to maintain the momentum. 

• What challenges and opportunities exist for Japanese outbound M&A amidst current geopolitical headwinds and the push for supply chain independence? 
• How can Japanese corporates best integrate overseas startups, and why are they noticeably absent from major non-tech global deals? 
• What are Japanese corporates buying to fuel their business model innovation, and how are they partnering with private equity to execute these deals?  
• How are Japanese firms using outbound M&A to hedge against the weak yen?

Amid fierce global competition and the looming threat of foreign takeovers, major legacy Japanese conglomerates have initiated a wave of domestic M&A focused on privatization and corporate carve-outs. These strategies allow them not only to shed non-core assets and refocus on core strengths, but also to shield themselves from earnings pressures. In many ways, these moves align with Japan's domestic context and national objectives, ultimately bolstering their global deal-making capabilities. However, they have also drawn criticism from activist investors and international companies concerned about the openness of the Japanese market.

• What is the status of non-core business carve-outs in Japan, and what are the main obstacles? 
• How are corporate M&A teams developing strategies to ensure they get the balance right? 
• How can engagement funds unlock the trapped potential of 'good' Japanese companies and transform them into the 'best'? 
• How can PE firms team up with Japanese management to provide the execution power they lack and facilitate these complex deals? 

Japan’s public M&A activity is in the midst of an unprecedented boom, driven by a powerful combination of corporate governance reforms and aggressive shareholder activism. Once a niche strategy, activism is now a primary catalyst for deal-making. However, concerns that the financial upside is "leaking" to foreign activist investors have alarmed both local cash-rich listed corporations and the new Japanese administration. In response, the market is bracing for potential protectionist policies, while targeted companies increasingly deploy PE-backed take-privates (delistings) as a primary defense mechanism.  

• How are Japanese corporations reacting as activist strategies evolve from aggressive to collaborative? 
• How are Japanese boards utilizing strategic defenses (carve-outs and take-privates) to pre-empt shareholder pressure? 
• How can private equity capitalize on the rising wave of activist-driven strategic defenses? 
• How might the regulatory environment change as a response to increased activist activity?

Japan’s soaring healthcare costs are pushing state pension funds to demand higher returns, driving nationwide corporate governance reforms aimed at boosting equity values, particularly within big pharma. Furthermore, given Japan's limited AI adoption, digital transformation and the acquisition of innovative technologies remain high on the corporate agenda. To secure stable, scalable, and high-tech-aligned assets, companies are turning to M&A as the most effective strategy to modernize, innovate, and grow. However, deals frequently stall during signing or exit planning, and many Japanese healthcare firms lack experience with massive, outbound mega-deals. In this panel, leading healthcare investors and industry experts will explore these challenges and uncover strategies for successful cross-border integration. 

• What is the M&A outlook for Japan's healthcare sector in 2027? 
• What characterizes the outbound M&A strategies of Japanese pharma companies? 
• Beyond transactions, how can Japanese healthcare M&A drive post-deal operational improvements, governance reform, and new business models? 
• What strategies are Japanese corporations using to invest in health-tech innovations and AI?  

Local and global private equity firms are capitalizing on favorable macroeconomic conditions, activist pressure and corporate governance tailwinds in Japan. Driven by a severe shortage of successors, Japanese SMEs are increasingly turning to the M&A market. However, while prime assets remain abundant, fierce competition and the gap between high valuations and actual profitability are making it difficult for PE firms to justify acquisition prices. Simultaneously, top Japanese PE players are aggressively raising new capital to seize these domestic opportunities and create a ‘national champions’ to compete at the top end of the deal spectrum.   

• What are the distinct approaches of domestic and global PE firms in penetrating the Japanese M&A market, and what can they draw from each other's playbooks? 
• As high valuations and intense competition price many out of the mega-deal space, has the mid-market officially become the primary battleground for PE alpha creation in Japan? 
• How can private equity firms use activist campaigns as catalysts for take-private transactions, and how do they address growing concerns about their association with activists? 
• Which exit channels will be most prolific over the next 12 months?